Cantor Fitzgerald Maintains Overweight on Pliant Therapeutics, Raises Price Target to $40

Cantor Fitzgerald analyst Pete Stravropoulos maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and raises the price target from $36 to $40.

Cantor Fitzgerald analyst Pete Stravropoulos maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and raises the price target from $36 to $40.

Total
0
Shares
Related Posts